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Background: B cell precursor acute lymphoblastic leukaemia (BCP-ALL) is the most common paediatric cancer.
BCP-ALL blasts typically retain wild type p53, and are therefore assumed to rely on indirect measures to suppress
transformation-induced p53 activity. We have recently demonstrated that the second messenger cyclic adenosine
monophosphate (cAMP) through activation of protein kinase A (PKA) has the ability to inhibit DNA damage-induced
p53 accumulation and thereby promote survival of the leukaemic blasts.
Development of BCP-ALL in the bone marrow (BM) is supported by resident BM-derived mesenchymal stromal
cells (MSCs). MSCs are known to produce prostaglandin E2 (PGE2) which upon binding to its receptors is able to elicit a
cAMP response in target cells. We hypothesized that PGE2 produced by stromal cells in the BM microenvironment
could stimulate cAMP production and PKA activation in BCP-ALL cells, thereby suppressing p53 accumulation and
promoting survival of the malignant cells.
Methods: Primary BCP-ALL cells isolated from BM aspirates at diagnosis were cocultivated with BM-derived MSCs, and
effects on DNA damage-induced p53 accumulation and cell death were monitored by SDS-PAGE/immunoblotting and
flow cytometry-based methods, respectively. Effects of intervention of signalling along the PGE2-cAMP-PKA axis were
assessed by inhibition of PGE2 production or PKA activity. Statistical significance was tested by Wilcoxon signed-rank
test or paired samples t test.
Results: We demonstrate that BM-derived MSCs produce PGE2 and protect primary BCP-ALL cells from p53
accumulation and apoptotic cell death. The MSC-mediated protection of DNA damage-mediated cell death is
reversible upon inhibition of PGE2 synthesis or PKA activity. Furthermore our results indicate differences in the
sensitivity to variations in p53 levels between common cytogenetic subgroups of BCP-ALL.
Conclusions: Our findings support our hypothesis that BM-derived PGE2, through activation of cAMP-PKA signalling in
BCP-ALL blasts, can inhibit the tumour suppressive activity of wild type p53, thereby promoting leukaemogenesis and
protecting against therapy-induced leukaemic cell death. These novel findings identify the PGE2-cAMP-PKA signalling
pathway as a possible target for pharmacological intervention with potential relevance for treatment of BCP-ALL.
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B cell precursor acute lymphoblastic leukaemia (BCP-ALL)
is a malignant neoplasm that occurs in both children and
adults, with approximately 1 in 2000 developing the disease
during childhood [1]. BCP-ALL is treated with multimodal
chemotherapy, and the overall survival is approaching
90% [2,3]. In spite of major improvements in treatment
outcome over the last decades, there are major chal-
lenges remaining. High risk subgroups defined by various
cytogenetic, biochemical, and clinical criteria have infer-
ior outcomes [1]. Relapses also occur in children with
standard risk features, accounting for more than a third
of the total BCP-ALL-associated death toll [2]. Further-
more, it is well-documented that survivors experience a
wide range of serious long-term treatment-associated
side effects such as secondary cancers, chronic organ
damage, cognitive, and psychosocial difficulties [4-7],
emphasizing the need for further improvement of treat-
ment strategies.
Paediatric BCP-ALLs generally retain wild type p53
[8], and are thus forced to suppress p53 activity through
indirect measures. We have previously demonstrated
that elevated levels of cyclic adenosine monophosphate
(cAMP) can suppress DNA damage-induced p53 accu-
mulation by promoting the interaction between p53 and
its negative regulator HDM2, thereby attenuating the
resulting cell death in BCP-ALL blasts [9-11]. cAMP is
an important physiological signal transducer in lympho-
cytes [12-14], and it is generated by adenylate cyclase
(AC) upon ligand binding to a subgroup of G protein-
coupled receptors (GPCRs) activating the stimulatory
alpha subunit Gαs. This, together with our observation that
cAMP attenuates the expression of p53 led us to postulate
that elevated cAMP levels might function as a tumour pro-
moting mechanism in development of BCP-ALL. The basal
levels of intracellular cAMP in isolated BCP-ALLs are
comparable to those of normal BCPs [11], and we there-
fore considered the possibility that BCP-ALLs could
produce high levels of cAMP in response to certain
physiological extracellular signals.
It has become increasingly clear that the biology of
cancer cannot be understood simply by elucidating the
cell-autonomous properties of the transformed cell popu-
lation. Cancer cells live in a complex interrelation with
non-transformed cells and extracellular matrix consti-
tuting the tumour microenvironment (ME), which play
decisive roles in the development of malignant disease
[15]. Much of the research into the role of tumour ME
has been conducted in carcinomas in which diverse cell
types such as endothelial cells, pericytes, immune inflam-
matory cells, and cancer-associated fibroblasts have been
recognized to play crucial roles in malignant progression
and the metastatic process [15]. Importantly, the bone
marrow (BM) has increasingly been implicated as a keysource of tumour-associated stromal cells, and evidence
suggests that BM mesenchymal stem and progenitor
cells are recruited to tumour sites where they can trans-
differentiate into cells participating in tumour develop-
ment, immunomodulation, and metastatic niche formation
[16]. Such MSCs can even be transformed by inflammation
to become neoplastic carcinoma cells [17].
Being an inherent malignant disease of the bone
marrow, ALL blasts have immediate access to BM
mesenchymal stromal cells (MSCs). In the BM, distinct
niches are thought to exist, providing signals necessary to
maintain and regulate haematopoiesis. Early lymphoid
progenitors reside in a niche that is spatially and cellularly
distinct from the haematopoietic stem cell niche [18].
BM-MSCs have been shown to support ALL blast engraft-
ment and survival through a variety of factors mediated
by cell-cell contact [19,20], or secretion of paracrine
signalling molecules [21]. MSCs have also been reported
to promote leukaemia development more indirectly
through local immune suppression [22].
BM-MSCs are known to secrete prostaglandin E2 (PGE2)
[23], and ALL blasts have been demonstrated to express
functional EP2 receptors, one of the AC-activating sub-
classes of PGE2 receptors [24,25]. The role of tumour
stroma-derived PGE2 has been extensively studied in solid
tumours [26], however, little is known about its potential
role in leukaemia physiology. Having recently shown that
PGE2 can suppress the p53 levels and cell death when
added to cell cultures of BCP-ALL cells [11], we have now
explored the possible role of BM stroma-derived PGE2 on
BCP-ALL p53 levels and cell survival. In agreement with
our hypothesis, our results suggest that bone marrow
microenvironment (BMME)-secreted PGE2, through its
inhibitory effects on p53 accumulation and cell death,
could contribute to the protective effect of the BMME
towards BCP-ALL cells. Furthermore, our results identify
BMME-derived PGE2 signalling as a possible target in
treatment of BCP-ALL.
Results
Cocultivation with MSC protects primary BCP-ALL cells
from cell death
Previous work from our group demonstrated that PGE2,
a naturally occurring eicosanoid secreted by the BMME,
could replicate the effects of augmented cAMP levels to
inhibit basal and DNA damage-induced p53 levels and
cell death in primary BCP-ALL blasts [9,11]. We there-
fore hypothesized that PGE2 secreted by the BMME,
through inhibitory effects on p53 accumulation and cell
death, could contribute to the protective effect of the
BMME towards BCP-ALL cells. To investigate this
possibility further, we first needed to establish an in vitro
model of BM protection of primary BCP-ALL cells. To
this end, BCP-ALL blasts from ALL5 were cocultured on
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iMSC#3. After 2 hours of coculture, the blasts were briefly
removed and irradiated with 2 Gy of ionising radiation
(IR). The cells were then reintroduced to the coculture
and harvested after 20 hours for examination of cell death
by propidium iodide (PI) staining and FACS analysis of
the CD19+ cell fraction. The choice of IR as model system
for inducing DNA damage has previously been discussed
[11], and we have demonstrated similar effects of cAMP
signalling on DNA-damaging cytostatic drugs such as
anthracyclins, cyclophosphamide, and cisplatin [9]. As
shown in Figure 1A, iMSC#3 in coculture significantly
protected the leukaemic blasts against both spontaneous
and IR-induced cell death.
To ascertain that the protective effect of iMSC#3 was
not restricted to this cell line, primary MSCs were iso-
lated and cocultured with BCP-ALL blasts from ALL5
and ALL16 under the same conditions as in Figure 1A.
Similar to iMSC#3, the primary MSC layers provided a
statistically significant protection against cell death with
median reduction of IR-induced cell death of 45% (range
28%-74%) (Figure 1B). To examine the generality of this
finding, isolated leukaemic blasts from nine different pa-
tients were subjected to 2 Gy of IR in the presence or
absence of iMSC#3 as described above, and the resulting
cell death was measured. As can be seen from the upper
panel of Figure 1C, all patient samples displayed protec-
tion from cell death upon coculture with stromal cells.
However, the relative degree of protection varied between
the samples (Figure 1C, lower panel). Interestingly,
t(12;21)-positive samples displayed a very weak protec-
tion against DNA damage-induced cell death, correlat-
ing with the inability of cAMP-elevating compounds to
enhance the survival of ALL-blasts from patients with
this particular translocation [11].
MSC coculture inhibits DNA damage-induced p53
accumulation in primary BCP-ALL cells
The ability of both BM stroma and cAMP-enhancing
agents to inhibit DNA damage-induced cell death led us
to investigate whether stromal coculture would affect
p53 levels. We cultured BCP-ALL cells from ALL5 with
or without a supporting BM stromal colayer for 2 hours
before subjecting the cells to 2 Gy of IR. After irradi-
ation, BCP-ALL cells were allowed to remain in cocul-
ture for another 2 hours before being removed from the
cocultures and analysed for the expression of p53. As
can be seen from Figure 2A, unirradiated cells express
low levels of p53. As expected, irradiation of the cells
led to an approximately four-fold increase in p53 levels,
an event that was significantly inhibited upon coculture
of irradiated cells with BM stromal cells. Due to the rela-
tively high numbers of cells required to perform SDS-
PAGE/IB, we were not able to analyse the impact ofstromal cells on p53 levels in all collected patient sam-
ples. However, stromal colayers were found to exert a
similar inhibitory effect on p53 levels on cells from
ALL6 and ALL17 as was shown for ALL5 (see Figure 2A
and B). To exclude the possibility that the results
obtained in Figures 1 and 2 could potentially be due to
engulfment of early apoptotic cells by phagocytic cells
present in the MSC colayer, thus selecting for more
viable cells with less p53 available for analysis, we
examined representative colayers with confocal mi-
croscopy and found no evidence of phagocytic activity
by the iMSC cells (data not shown).
MSC colayers produce PGE2
Having demonstrated that colayers of MSC cells could
mimic the effect of PGE2, cAMP induction, or PKA ago-
nists on p53 levels and cell death in BCP-ALL cultures
[11], we proceeded to examine the hypothesis that
prosurvival signalling from BM stroma could in part be
mediated through signalling cascades involving the
PGE2-cAMP-PKA axis. To this end, we first wished to
ensure that the stromal colayers indeed secreted PGE2.
For this purpose iMSC#3 cells were grown to con-
fluency before changing the growth medium. Superna-
tants were collected 24 hours after addition of fresh
medium to the cell cultures, and PGE2 concentrations
were measured as described in Materials and Methods.
As can be seen from the left panel of Figure 3, the PGE2
concentrations in MSC supernatants varied between
experiments, with a median value of approximately
200 ng/ml. The supernatants of BCP-ALL monocultures
contained negligible levels of PGE2, indicating that
autocrine supply of PGE2 by the leukaemic blasts is
likely to be minimal. As there have been reports on
paracrine loops in which cancer cells induce PGE2
synthesis in neighbouring MSCs or fibroblasts [23,27],
we also measured the PGE2 concentration in superna-
tants of BCP-ALL/MSC cocultures. As can be seen from
the left panel of Figure 3, there was no substantial in-
duction of PGE2 synthesis by the MSC cells as a result
of coculture. PGE2 is an eicosanoid produced from
arachidonate by an enzymatic reaction catalysed by
cyclooxygenase (COX), and the COX1/2 inhibitor
indomethacin is a potent inhibitor of its biosynthesis.
As expected, addition of indomethacin to the cocul-
tures efficiently suppressed PGE2 production (Figure 3,
right panel).
The protective effect of MSC coculture depends on PGE2
production and PKA signalling
Having demonstrated that indomethacin inhibits the
secretion of PGE2 by MSCs, we proceeded to investigate
the possibility that indomethacin could reverse the prosur-
vival effect of iMSC#3 in cocultures. Monocultures or
Figure 1 (See legend on next page.)
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Figure 1 MSC coculture protects primary BCP-ALL cells from cell death. (A) Isolated BCP-ALL blasts from ALL5 were cultured in the absence
or presence of a confluent layer of iMSC #3. After 2 h, the blasts were briefly removed from the coculture and irradiated with 2 Gy of IR. The cells were
then reintroduced to the coculture and harvested after 20 h for examination of cell death in the CD19+ cell fraction by CD19-FITC/PI co-staining as
described in Materials and Methods. The histogram shows mean values of 10 independent experiments, with error bars indicating SEM values.
*P < 0.0001 by paired samples t test. (B) Isolated BCP-ALL blasts from ALL5 (n = 3) and ALL16 (n = 3) cultured in the absence or presence of a
confluent layer of primary BM-MSC were treated and analysed as described in the legend to Figure 1A. The left panel shows absolute cell death
values for each experiment with bars representing median values. *P < 0.05 by Wilcoxon matched pairs signed rank test. The right panel shows
relative reduction in cell death mediated by MSC coculturing for each BCP-ALL sample at 0 Gy and 2 Gy of irradiation, respectively. The horizontal
bars represent median values. (C) Isolated BCP-ALL blasts from 9 different patient samples were treated and analysed as described in Figure 1A,
and grouped according to cytogenetic sub-classification. The upper panel shows absolute cell death values after 0 and 2 Gy of irradiation
(ALL5: n = 10, error bars represent SEM values; ALL16: n = 3, error bars represent SEM values; ALL18: n = 2, error bars represent range of values;
ALL6/10/12/17/19/20: values represent results from single experiments). The lower panel shows the relative reduction of cell death imposed by
iMSC#3 on irradiated BCP-ALL blasts.
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with 2 Gy of IR in the absence or presence of indometh-
acin. Whereas indomethacin had no effect on cell death
of BCP-ALL blasts in monocultures, it reversed the pro-
tective effect of the MSC colayer by approximately 30%
(Figure 4A). To test the reproducibility of this finding
across samples from different patients, a series of exper-
iments were performed on available t(12;21)-negative
samples. t(12;21)-positive samples were excluded as
these displayed a weak protective effect by MSC (see
Figure 1C, lower panel). As shown in the left panel of
Figure 4B, whereas indomethacin had a slight cytopro-
tective effect in the monoculture setting, it significantly
reversed the prosurvival effect of MSC layeres in cocul-
ture. The relative indomethacin-induced reversal of the
MSC-effect was calculated for each individual experi-
ment, and as shown in the right panel of Figure 4B, the
median reversal was 30% (range -3% to 64%). We also
verified that indomethacin could reverse the protective
effects of primary MSC layers upon cocultures with
ALL 16 (data not shown).
To further investigate whether the prosurvival effects
of MSC on BCP-ALL blasts could be conveyed by
PGE2-induced cAMP-PKA signalling, we took advan-
tage of the PKA antagonist Rp-8-Br-cAMPS. BCP-ALL
blasts from ALL5 in monocultures or in cocultures
with iMSC#3 were irradiated in the absence or pres-
ence of Rp-8-Br-cAMPS. Similar to indomethacin,
Rp-8-Br-cAMPS significantly reversed the protective
effect of MSC on IR-induced cell death in BCP-ALL
blasts (Figure 5), indicating that PKA-mediated signal-
ling is implicated in MSC-derived prosurvival signalling
in ALL.
Discussion
In the present paper we demonstrate that BM-derived
MSCs in coculture protect primary BCP-ALL cells from
DNA damage-induced p53 accumulation and cell death
in a PGE2-dependent manner. To our knowledge, BM-
induced suppression of p53 levels in leukaemia cells hasnot previously been reported. This novel finding may
not only improve our understanding of how BCP-ALL
develops, but also identifies the PGE2-cAMP-PKA sig-
nalling pathway as a possible target in the treatment of
BCP-ALL.
Eicosanoids, and in particular PGE2, have an estab-
lished role in cancer biology [26,28]. The role of PGE2 as
an autocrine and paracrine signalling molecule has been
particularly well-documented in carcinomas where it
has been shown to promote tumour cell proliferation,
survival, invasion and migration [26]. The anti-apoptotic
activity of PGE2 in this setting has mainly been attributed
to activation of the PI3K-Akt-PPARδ signalling axis [26].
To our knowledge, very little is known about the role
of PGE2 in haematopoietic malignancies, and we here
propose a distinct anti-apoptotic mechanism of PGE2 in
BCP-ALLs compared to what is established in carcin-
omas. Based on our findings that 1) exposure of BCP-
ALL cells to either forskolin, cAMP analogues, PGE2, or
MSC cocultures inhibits p53 accumulation and cell
death in a similar fashion [9-11], 2) MSCs secrete PGE2,
3) ALL cells are known to express functional EP2 recep-
tors eliciting a cAMP response [24], and 4) the effect of
MSC cocultures on BCP-ALL p53 levels and cell sur-
vival is inhibited by COX or PKA inhibitors, we suggest
a model in which BCP-ALL cells are protected from
DNA damage-induced p53 accumulation and cell death
by BM stromal cells in a PGE2-cAMP-PKA-dependent
manner (Figure 6). Furthermore, it should be noted that
we have observed a similar effect of cAMP on p53 in
carcinoma and sarcoma cell lines such as MCF-7 [10],
U2-OS [10], and HCT116 (unpublished results), sug-
gesting that inhibition of the tumour suppression func-
tion of wild type p53 by cAMP is not a phenomenon
restricted to BCP-ALL.
A striking observation in the present study is the lack
of cytoprotection of stromal coculture on blasts from t
(12;21)-positive BCP-ALL patients (Figure 1C). This is in
agreement with our previously reported lack of protective
effect of forskolin on DNA damage-induced cell death in
Figure 2 MSC coculture inhibits DNA damage-induced p53
accumulation in primary BCP-ALL cells. (A) BCP-ALL blasts from
ALL5 were cultured in the absence or presence of a confluent layer
of iMSC#3 and irradiated as described in Figure 1A. 2 h after IR, BCP-ALL
blasts were harvested, lysed and subjected to immunoblot analysis
with antibodies against p53 and actin. The immunoblot shows
one representative experiment of four. Densitometric analysis of
immunoblots was performed as described in Materials and Methods.
The histogram shows mean values with error bars indicating SEM
values (n = 4, *P < 0.05 by paired samples t test). (B) Cells from ALL6 or
ALL17 were treated as described in Figure 2A. 4 h after IR, BCP-ALL
blasts were harvested, lysed and subjected to immunoblot analysis
with antibodies against p53 and actin or GAPDH.
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supports the possible contribution of cAMP-mediated
signalling in MSC-driven prosurvival effects. Interest-
ingly, t(12;21)-positive and -negative samples display
similar p53 responses: p53 accumulates after irradiation,
and the radiation-induced p53 response can be attenu-
ated with the addition of forskolin or upon coculture
with MSCs. However, in t(12;21)-positive samples thereduction in p53 does not translate into reduced levels
of cell death [11]. One possible interpretation of this find-
ing is that t(12;21)-positive cells have a lower threshold for
p53-mediated induction of apoptosis than the other cyto-
genetic subgroups. The t(12;21) translocation results in
the transcription of an ETV6/RUNX1 fusion protein and
has been demonstrated to be the initiating event in the
transformation of this subgroup of ALL, occurring in
utero and resulting in a premalignant clone requiring
additional secondary genetic alterations to develop into
overt leukaemia [29-31]. It was recently published that
the ETV6/RUNX1 fusion protein can bind to the P2
promoter of the HDM2 gene and enhance its transcrip-
tion [32]. This could result in an inherent protection of
the t(12;21)-positive clones from oncogene-induced
p53 accumulation. When challenged with severe DNA-
damaging stress, such as ionising radiation or DNA-
damaging cytostatic drugs, the elevated HDM2 levels in
ETV6/RUNX1 positive BCP-ALL cells might no longer
suffice to suppress p53 accumulation, and cells suc-
cumb to p53-induced apoptosis in accordance with our
observations. In the presence of increased cAMP levels,
for instance induced by stromal cocultures, p53 accu-
mulates to a lesser extent, but appears to remain above
a threshold for effective apoptosis induction. This
might be in contrast to non-ETV6/RUNX1 expressing
BCP-ALL cells, which would be expected to have
evolved compensatory mechanisms to tolerate higher
p53 levels.
Among the t(12;21)-negative BCP-ALLs there are
cytogenetic subgroups with particularly poor prognosis,
such as the t(9;22) (Philadelphia chromosome)-positive
subtype represented by ALL5 in the present study [1].
Importantly, our findings suggest that pharmacological
intervention of PGE2-cAMP-PKA-mediated signalling
in t(12;21)-negative BCP-ALLs might provide a the-
rapeutic possibility to counteract the unfavourable
protective effects of the BM niche towards these cyto-
genetic subtypes of BCP-ALLs. An obvious pharmaceut-
ical candidate based on our results is non-steroidal anti-
inflammatory drugs (NSAIDs), of which indomethacin
is an example. NSAIDs are well-established in clinical
use as analgetic and anti-inflammatory drugs, and are
tolerated with manageable side effects. PKA inhibitors
such as Rp-8-Br-cAMPS are not yet approved for clin-
ical use, but have been tested in animal models without
apparent severe toxicity [33,34]. An alternative ap-
proach could be stimulation of opioid receptors, which
belong to a subgroup of GPCRs coupled to Gαi subunits
able to inhibit the AC and thereby cAMP generation. In
line with the latter approach, it was recently published
that D,L-methadone, through binding to opioid receptors,
sensitized leukaemia cells to DNA damage-induced cell
death by doxorubicin [35].
Figure 3 iMSC#3 secretes PGE2, which can be inhibited by Indomethacin. iMSC#3 cells were grown to confluency, and growth medium
was changed from MEMα to RPMI with or without Indomethacin as indicated. After 24 h, primary BCP-ALL cells were added as indicated and cocultures
incubated for an additional 24 h. Supernatants were subsequently subjected to analysis of prostaglandin E2 levels by EIA as described in Materials and
Methods. The results are presented as scatter plots with horizontal bars representing median values. *P< 0.05 by Wilcoxon matched pairs signed rank test.
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biting PGE2 synthesis might already be exploited in
conventional BCP-ALL treatment. Glucocorticoids
(GCs), which constitute a backbone of modern BCL-
ALL treatment, are known to attenuate the synthesis ofFigure 4 Indomethacin reverses MSC-mediated cell death protection
medium was changed from MEMα to RPMI with or without Indomethacin
monolayer for 2 h before removal for irradiation with 2 Gy. BCP-ALL blasts we
and cocultured for 20 h prior to cell death analysis of the CD19+ cell fraction
histogram shows mean values of five independent experiments with error ba
Indomethacin, and analysed as described in 4A. Left panel: The scatter plot re
(ALL5: n = 5; ALL6: n = 1, ALL16: n = 4, ALL17: n = 1, ALL19: n = 1, ALL20: n = 1
matched pairs signed rank test. Right panel: The relative reversal of iMSC#3 effec
the following formula: ([“+IR, +MSC, +Indo” − “+IR, +MSC, −Indo”] / [“+IR, −
as a scatter plot with the horizontal bar representing the median value.prostaglandins via inhibition of phospholipase A2 and
COX2 expression [36]. The importance of GC-induced
inhibition of PGE2 has to our knowledge mainly been
discussed in relation to the anti-inflammatory proper-
ties of GCs, whereas more direct proapoptotic effectsin BCP-ALL. (A) iMSC#3 cells were grown to confluency before growth
as indicated. After 24 h, ALL5 cells were cocultured with the iMSC#3
re reintroduced to the iMSC#3 monolayer immediately after irradiation
by CD19-FITC/PI co-staining as described in Materials and Methods. The
rs indicating SEM values. (B) ALL blasts were cocultured, treated with
presents absolute cell death values from 13 independent experiments
), with horizontal bars indicating median values. *P < 0.01 by Wilcoxon
t in irradiated (IR) cells by Indomethacin (Indo) was calculated according to
MSC, −Indo” − “+IR, +MSC, −Indo”]) × 100% . The values are displayed
Figure 5 PKA antagonist reverses MSC-mediated cell death
protection in BCP-ALL. iMSC#3 cells were grown to confluency
before growth medium was changed from MEMα to RPMI with or
without Rp-8-Br-cAMPS as indicated. After 24 h, ALL5 cells were
cocultured with the iMSC#3 monolayer for 2 h before removal for
irradiation with 2 Gy. BCP-ALL blasts were reintroduced to the iMSC#3
monolayer immediately after irradiation and cocultured for 20 h prior to
cell death analysis of the CD19+ cell fraction by CD19-FITC/PI co-staining
as described in Materials and Methods. The histogram shows mean
values of seven independent experiments with error bars indicating
SEM values. **P < 0.01, *P < 0.05 by paired samples t test.
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properties [37]. We have observed a reduction of PGE2
concentration in supernatants of MSCs treated with
dexamethasone (data not shown). If a similar trend can
be observed in clinical BM specimens collected before
and after the onset of GC-based therapy, this would
encourage further investigation into the role of PGE2
suppression in the antileukaemic effect of GCs.Figure 6 Proposed model for MSC-derived PGE2-mediated cytoprotec
prostaglandin E2 (PGE2) by the enzymatic conversion of arachidonic acid (AA)
then secreted into the extracellular space where it can signal in a paracrine m
of B cell precursor acute lymphoblastic leukaemia (BCP-ALL) cells. Binding of P
conversion of ATP to cAMP, which further activates target proteins such as prot
cells thereby inhibiting DNA damage-induced p53-dependent cell death. Non-s
with this cascade of events with the potential of reversing the MSC-mediated pComplementing the understanding of the biological ef-
fects of GCs in leukaemia would be important, as GC re-
sistance in BCP-ALL represents a major adverse
prognostic factor, and the mechanisms of such resistance
is incompletely understood [37,38].Conclusion
We believe our results presented in the present paper
lend strong support to the hypothesis that BM-derived
MSCs can supply BCP-ALL cells with prosurvival
signals acting through a PGE2-cAMP-PKA-axis even-
tually attenuating the p53 response. This signalling
cascade can be of importance both during the preleu-
kaemic phase by suppressing oncogene-induced p53,
and during leukaemia therapy by suppressing DNA
damage-induced p53. Furthermore, our results suggest
targets for pharmacological intervention in this signal-
ling pathway to counteract the so called chemopro-
tective niche in the BM, either by inhibiting PGE2
production by NSAIDs or GCs, by inhibiting AC acti-
vation by stimulation of the opioid receptor, or by
direct PKA inhibition. Given that our in vitro findings
can be replicated in a clinical setting, we hope our
results can ultimately contribute to improvement of
current leukaemia treatment by allowing increased
antileukaemic effect of a given dose of a cytostatic drug.
This could be exploited either to increase the efficacy of
current treatment regiments, or alternatively to reduce
currently applied doses of cytostatic drugs to prevent side
effects whilst retaining the antileukaemic efficacy.tion of BCP-ALL. Mesenchymal stromal cells (MSC) produce
in a process depending on the action of cyclooxygenases (COX). PGE2 is
anner by binding to the E prostanoid receptor 2 (EP2) on the surface
GE2 to EP2 activates adenylate cyclase (AC) resulting in the enzymatic
ein kinase A (PKA). PKA activation attenuates p53 accumulation in BCP-ALL
teroidal anti-inflammatory drugs (NSAIDs) or PKA inhibitors can interfere
rotection of BCP-ALL cells during DNA-damaging therapy.
Naderi et al. Molecular Cancer  (2015) 14:14 Page 9 of 12Methods
Reagents, antibodies and radiation treatment
Forskolin and propidium iodide (PI) were purchased from
Sigma-Aldrich (St. Louis, MO). Rp-8-Br-cAMPS was a
kind gift from Professor Kjetil Taskén (The Biotechnology
Center of Oslo, University of Oslo, Norway). Antibodies
against p53 (DO-1) and actin (C-2) were from Santa Cruz
Biotechnology (Santa Cruz, CA), whereas antibodies
against GAPDH were from Sigma-Aldrich. C19-FITC
antibodies were from Miltenyi Biotech (Bergisch Gladbach,
Germany) and CD10-PE-Cy™5 from BD Pharmingen
(San Jose, CA). For treatment with γ-radiation, cells
were exposed to a 137Cs source at a dose rate of
4.3 Gy/min using a Gammacell irradiator from MSD
Nordion (Ottawa, Canada).Cell lines, primary cell isolation and cell culture
The immortalised bone marrow derived human mesen-
chymal stroma cell line iMSC#3 [39] was generated by
transduction with the pBabe-puro-hTert adeno virus
[40], is nontumourigenic, has a normal karyotype, and
has maintained its osteogenic and adipogenic potential,
as well as the ability to support B cell maturation [41].
Cells were maintained at 30-80% confluence in MEM
alpha medium supplemented with 10% foetal bovine
serum (FBS), 100 U/ml penicillin, and 100 μg/ml
streptomycin (PS). Cultures of primary bone marrow
stromal cells were established from bone marrow
samples obtained from healthy volunteers. 10 ml bone
marrow aspirate was mixed with 500 μl 2% methylcellu-
lose and left to sediment for 60 min. The buffy-coat was
cultured at a density of 3×106 cells/ml in IMDM medium
supplemented with 12.5% horse serum, 12.5% FBS,
100 μM β-mercaptoethanol, 100 μM hydrocortisone, and
PS. Adherent cells reached confluence after 2-3 weeks,
and the cell culture was used for experiments within the
first week thereafter. Alternatively, BM was diluted 1:3 in
DMEM/F12-Glutamax before density centrifugation in
Lymphoprep (Axis-Shield, Dundee, Scotland). Mono-
nuclear cells were seeded, and adherent cells cultured as
above. 24 hours prior to coculture with BCP-ALL blasts,
the medium of MSC cells was changed to supplemented
RPMI (see below). Primary BCP-ALL blasts were isolated
from bone marrow aspirates performed at diagnosis as
previously described [9]. The proportion of CD10+CD19+
blasts was assessed by costaining with CD10-PE-Cy™5 and
CD19-FITC antibodies followed by flowcytometric ana-
lysis on a FACS Calibur instrument (BD Biosciences, NJ).
BCP-ALL blasts were cultured at 106 cells/ml in RPMI
medium supplemented with 10% FBS and PS. The
collection of bone marrow aspirates from patients and
healthy volunteers has been approved by the Regional
Ethics Committee of Norway, region Sør-Øst A, andrecommended by Competent Authorities. Patient charac-
teristics are outlined in Table 1.
Selection of patient samples for different experiments
Upon isolation of BCP-ALL blasts from patients, the
resulting cell yield and viability after freezing and
thawing was very variable between samples. Patient
samples were prioritized into different experiments
accordingly. Collection of samples was performed in
continuity with previous projects [9,11], with samples
ALL14-21 collected with primary use for the current
project. ALL14 and 15 was excluded due to very poor
viability and cell yield respectively. In addition, frozen
material from previously collected material has been
used when available (ALL5, 6, 10 and 12). As t(12;21)-
positive samples display poor protection from MSC
coculture, these were excluded from experiments
examining the potential reversibility of this effect by
COX or PKA inhibitors. Of available t(12;21)-negative
samples, only cell yield/viability upon thawing from
patient 5 and patient 16 was sufficient to perform
repeated experiments with cocultures and COX or
PKA inhibitors.
Measurement of cell death, immunoblotting and
densitometric analysis
Measurement of cell death in the CD19-positive fraction,
immunoblot (IB) analysis, densitometric analysis, and
normalization of densitometric values was performed as
previously described [9,11].
Quantification of PGE2 concentration in culture
supernatant
The concentration of PGE2 in culture supernatants was
determined by competitive enzyme immuno assay (EIA)
using the Prostaglandin E2 EIA Kit – Monoclonal from
Cayman Chemical Company (Ann Arbor, MI). Experi-
ments were performed according to the manufacturer’s
procedure. For each sample, two parallel aliquots were
run, and the optical density of standards and samples at
a wavelength of 405 nm was determined using a
Multiscan Ex microplate reader (Thermo Scientific,
Waltham, MA). The results were analysed using a data
analysis tool provided online by the manufacturer at
www.caymanchem.com/analysis/eia.
Statistical methods and calculation
SPSS 14.0.2 for Windows was used to perform statistical
analysis. The paired samples t test was used to test the
significance of differences in series of experiments run
on cells from the same patient source, whereas the
Wilcoxon signed-rank test was used to test the signifi-
cance of differences observed in series of experiments
run on cells from different patients.
Table 1 Patient characteristics
Patient sample ALL5 ALL6 ALL10 ALL12 ALL16 ALL17 ALL18 ALL19 ALL20 ALL 21
Age (years.months) 14.5 5.0 15.6 3.4 2.8 3.2 6.5 7.5 7.4 11.7
Sex Female Female Female Female Male Male Male Male Male Male
Sample from relapse No Yes No No No No No No No No
Immunophenotype Common-B Common-B Common-B Pre-B Pre-B Pre-B Pre-B Pre-B Pre-B Pre-B
Cytogenetics t(9;22) Normal karyotype t(12;21)t(5;17) t(12;21)(p13;q22) 47 ~ 48,XY,+X,i(21)(q10),+
i(21)(q10),[cp9]/46,XY[1]





Residual disease at day 15 42 × 10-2 Not performed 30 × 10-2 1.1 × 10-2 3.2 × 10-3 8.9 × 10-3 8 × 10-3 No MRD 5 x 10-3 No MRD
Residual disease at day 29 27 × 10-2 No MRD 7.3 × 10-3 3 × 10-4 No MRD 9 × 10-4 5 × 10-4 No MRD No MRD No MRD
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